Search Results

There are 8261912 results for: content related to: Nilotinib versus imatinib

  1. You have free access to this content
    Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia

    Cancer

    Volume 118, Issue 2, 15 January 2012, Pages: 300–311, Jerald P. Radich

    Version of Record online : 29 JUN 2011, DOI: 10.1002/cncr.26280

  2. You have free access to this content
    Practical management of patients with chronic myeloid leukemia

    Cancer

    Volume 117, Issue 19, 1 October 2011, Pages: 4343–4354, Francisco Cervantes and Michael Mauro

    Version of Record online : 16 MAR 2011, DOI: 10.1002/cncr.26062

  3. You have full text access to this OnlineOpen article
    Suboptimal responses in chronic myeloid leukemia

    Cancer

    Volume 118, Issue 5, 1 March 2012, Pages: 1181–1191, Elias Jabbour, Giuseppe Saglio, Timothy P. Hughes and Hagop Kantarjian

    Version of Record online : 28 OCT 2011, DOI: 10.1002/cncr.26391

  4. Current and Future Clinical Strategies in the Management of Chronic Myeloid Leukemia

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 30, Issue 9P2, September 2010, Pages: 77S–101S, Kamakshi V. Rao, Andrea Iannucci and Elias Jabbour

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.30.pt2.77S

  5. You have free access to this content
    Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia

    European Journal of Clinical Investigation

    Volume 42, Issue 9, September 2012, Pages: 1016–1026, Francis Giles, François-Xavier Mahon, Bjorn Gjertsen, Ronan Swords, Boris Labar, Anna Turkina and Gianantonio Rosti

    Version of Record online : 1 MAY 2012, DOI: 10.1111/j.1365-2362.2012.02675.x

  6. You have free access to this content
    Nilotinib, imatinib, and telomere homeostasis disruption in chronic myeloid leukemia

    Cancer

    Volume 118, Issue 20, 15 October 2012, Page: 5183, Franck E. Nicolini, Paul W. Manley and Tim H. Brümmendorf

    Version of Record online : 25 APR 2012, DOI: 10.1002/cncr.27481

  7. Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: An insight

    Clinical and Experimental Pharmacology and Physiology

    Volume 41, Issue 10, October 2014, Pages: 788–797, Gamal E Shiha, Nashwa M Abu-Elsaad, Khaled R Zalata and Tarek M Ibrahim

    Version of Record online : 30 OCT 2014, DOI: 10.1111/1440-1681.12286

  8. You have free access to this content
    Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring

    American Journal of Hematology

    Volume 91, Issue 2, February 2016, Pages: 252–265, Elias Jabbour and Hagop Kantarjian

    Version of Record online : 22 JAN 2016, DOI: 10.1002/ajh.24275

  9. You have free access to this content
    Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop

    American Journal of Hematology

    Volume 86, Issue 9, September 2011, Pages: 811–819, Tariq I. Mughal, Jerald P. Radich, Richard A. Van Etten, Alfonso Quintás-Cardama, Tomasz Skorski, Farhad Ravandi, Daniel J. DeAngelo, Carlo Gambacorti-Passerini, Giovanni Martinelli and Ayalew Tefferi

    Version of Record online : 17 AUG 2011, DOI: 10.1002/ajh.22097

  10. Enzyme- and Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors

    Journal of Pharmaceutical Sciences

    Volume 103, Issue 12, December 2014, Pages: 3810–3833, Jie Shao, John S. Markowitz, Di Bei and Guohua An

    Version of Record online : 10 OCT 2014, DOI: 10.1002/jps.24113

  11. You have free access to this content
    Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia

    Cancer

    Volume 121, Issue 6, March 15, 2015, Pages: 863–871, Avichai Shimoni, Yulia Volchek, Maya Koren-Michowitz, Nira Varda-Bloom, Raz Somech, Noga Shem-Tov, Ronit Yerushalmi and Arnon Nagler

    Version of Record online : 11 NOV 2014, DOI: 10.1002/cncr.29141

  12. You have free access to this content
    Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management

    American Journal of Hematology

    Volume 87, Issue 11, November 2012, Pages: 1037–1045, Elias Jabbour and Hagop Kantarjian

    Version of Record online : 23 OCT 2012, DOI: 10.1002/ajh.23282

  13. You have free access to this content
    Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remission

    American Journal of Hematology

    Volume 90, Issue 3, March 2015, Pages: 242–249, Harry P. Erba

    Version of Record online : 30 JAN 2015, DOI: 10.1002/ajh.23902

  14. You have free access to this content
    How I treat newly diagnosed chronic myeloid leukemia in 2015

    American Journal of Hematology

    Volume 90, Issue 2, February 2015, Pages: 156–161, Carlo Gambacorti-Passerini and Rocco Piazza

    Version of Record online : 24 NOV 2014, DOI: 10.1002/ajh.23887

  15. Nilotinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 28, Issue 11, November 2008, Pages: 1374–1382, Anthony Jarkowski and Richard P. Sweeney

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.28.11.1374

  16. Treatment-, Patient-, and Disease-Related Factors and the Emergence of Adverse Events with Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 33, Issue 8, August 2013, Pages: 868–881, Elizabeth Irvine and Casey Williams

    Version of Record online : 3 APR 2013, DOI: 10.1002/phar.1266

  17. You have free access to this content
    Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: E66–E72, Jorge Cortes, Michael Mauro, Juan Luis Steegmann, Giuseppe Saglio, Rachpal Malhotra, Jon A. Ukropec and Nicola T. Wallis

    Version of Record online : 30 JAN 2015, DOI: 10.1002/ajh.23938

  18. You have free access to this content
    Expanding Nilotinib Access in Clinical Trials (ENACT)

    Cancer

    Volume 118, Issue 1, 1 January 2012, Pages: 118–126, Franck E. Nicolini, Anna Turkina, Zhi-Xiang Shen, Neil Gallagher, Saengsuree Jootar, Bayard L. Powell, Carmino De Souza, Ming Zheng, Tomasz Szczudlo and Philipp le Coutre

    Version of Record online : 5 JUL 2011, DOI: 10.1002/cncr.26249

  19. You have free access to this content
    Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

    Cancer

    Volume 121, Issue 21, November 1, 2015, Pages: 3894–3904, Musa Yilmaz, Amit Lahoti, Susan O'Brien, Graciela M. Nogueras-González, Jan Burger, Alessandra Ferrajoli, Gautam Borthakur, Farhad Ravandi, Sherry Pierce, Elias Jabbour, Hagop Kantarjian and Jorge E. Cortes

    Version of Record online : 28 JUL 2015, DOI: 10.1002/cncr.29587

  20. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years

    Journal of Clinical Pharmacy and Therapeutics

    Volume 40, Issue 4, August 2015, Pages: 391–397, A.-S. Lang, M. Mounier, M. Roques, M. L. Chretien and M. Boulin

    Version of Record online : 10 APR 2015, DOI: 10.1111/jcpt.12273